UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/830,089	04/23/2004	Craig Jordan	50229-436	7583
McDemott, Wil	7590 04/24/200 <b>1 &amp; Emerv</b>	EXAMINER		
600 13th Street, Washington, DO	N.W.	BELYAVSKYI, MICHAIL A		
washington, De	20003-3090		ART UNIT	PAPER NUMBER
			1644	
		MAIL DATE	DELIVERY MODE	
			04/24/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application	n No.	Applicant(s)				
		10/830,08	9	JORDAN, CRAIG				
	Office Action Summary	Examiner		Art Unit				
		Michail A.	Belyavskyi	1644				
Period fo	The MAILING DATE of this communication or Reply	appears on the	cover sheet with the c	orrespondence ad	ddress			
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING asions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. It is period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by state that the period by the Office later than three months after the material part of the provided patent term adjustment. See 37 CFR 1.704(b).	DATE OF THE ALL STATES AND ALL STATE	IS COMMUNICATION int, however, may a reply be tind the spire SIX (6) MONTHS from the ication to become ABANDONE	N. nely filed the mailing date of this of D (35 U.S.C. § 133).				
Status								
1)	Responsive to communication(s) filed on 24	5 February 201	00					
·	Responsive to communication(s) filed on <u>25 February 2009</u> .  This action is <b>FINAL</b> .  2b) This action is non-final.							
3)	<i>'—</i>			secution as to the	e merits is			
٥,١	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠	Claim(s) <u>23,58-66,72 and 76</u> is/are pending	in the applica	tion.					
-	4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) is/are allowed.							
·	6)⊠ Claim(s) is/are allowed. 6)⊠ Claim(s) <u>23,58-66,72 and 76</u> is/are rejected.							
· ·	Claim(s) is/are objected to.							
•	Claim(s) are subject to restriction an	nd/or election re	equirement.					
	on Papers		•					
		ninor						
•	The specification is objected to by the Exam		abjected to by the I	Evaminor				
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
	ınder 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
2) 🔲 Notic 3) 🔯 Infori	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date 11/24//08.	)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate				

## RESPONSE TO APPLICANT'S AMENDMENT

Page 2

1. Applicant's amendment, filed 02/25/09 is acknowledged.

Claims 23, 58-66, 72 and 76 are pending.

Claims 23, 58-66, 72 and 76 drawn to a method for impairing cancerous progenitor cells in a patient comprising administering to said patient a composition comprising an antibody conjugated to cytotoxic agent, wherein said composition binds selectively to CD123 are under consideration in the instant application.

In view of the amendment, filed 02/25/09 the following rejection remains

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Art Unit: 1644

3. Claims 23, 58-66, 72 and 76 stand rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-6 of U.S. Patent No.6,733,743 for the same reasons set forth in the previous Office Action, mailed on 09/26/08.

Although the conflicting claims are not identical, they are not patentably distinct from each other because 1-6 of U.S. Patent No.6,733,743 recites a method of impairing a hematologic cancer progenitor cells that expresses CD123, comprising contacting said cells with a composition comprising an antibody and a cytotoxic agent, wherein said antibody binds selectively to CD123.

It is noted that applicant indicated that he will consider the filing of a terminal disclamer.

- 4. No claim is allowed.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571/272-0735.

The fax number for the organization where this application or proceeding is assigned is 571/273-8300

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Michail A Belyavskyi/ Primary Examiner, Art Unit 1644 Application/Control Number: 10/830,089

Page 4

Art Unit: 1644